Future Virology最新文献

Working towards a single-dose vaccine for rabies post-exposure prophylaxis. 致力于开发单剂狂犬病暴露后预防疫苗。

IF 1 4区医学

Future Virology Pub Date : 2026-01-01 Epub Date: 2026-05-06 DOI: 10.1080/17460794.2026.2667092

Tyler P Graf, Kevin J McHugh

{"title":"Working towards a single-dose vaccine for rabies post-exposure prophylaxis.","authors":"Tyler P Graf, Kevin J McHugh","doi":"10.1080/17460794.2026.2667092","DOIUrl":"10.1080/17460794.2026.2667092","url":null,"abstract":"Rabies is almost universally fatal if not treated before symptoms appear. Fortunately, post-exposure prophylaxis (PEP) is a nearly 100% effective treatment when started soon after rabies exposure. Nevertheless, rabies causes approximately 59,000 deaths annually, predominantly in rural parts of low- and middle-income countries. Current World Health Organization rabies PEP protocols require 1) a single administration of rabies immunoglobulin and 2) three or four doses of a vaccine administered over one to two weeks. The need for multiple healthcare visits significantly reduces treatment adherence due to financial, geographic, and other logistical barriers. Single-dose vaccine strategies represent a potential avenue to overcome these limitations by consolidating the vaccine dosing regimen into a single clinical interaction with a healthcare professional. This narrative review highlights several of the most promising technologies being used to pursue this goal, including mRNA vaccines, controlled-release formulations, and microneedle delivery systems. Although these strategies have yet to achieve clinical success in humans, data generated in preclinical studies and clinical trials offer insight into the limitations and potential benefits of these approaches as the field continues to seek a single-dose vaccine for PEP treatment. Highlighted articles were found by searching PubMed and Google Scholar, and published between January 2015 and August 2025.","PeriodicalId":12505,"journal":{"name":"Future Virology","volume":"21 4","pages":"275-288"},"PeriodicalIF":1.0,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13215696/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148053741","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

When defense backfires: inflammatory determinants of RSV-induced disease severity. 当防御适得其反：rsv诱导的疾病严重程度的炎症决定因素。

IF 1 4区医学

Future Virology Pub Date : 2026-01-01 Epub Date: 2026-07-22 DOI: 10.1080/17460794.2026.2705137

Alexandra Y Chasse, Ann M Miller, Steven M Varga

{"title":"When defense backfires: inflammatory determinants of RSV-induced disease severity.","authors":"Alexandra Y Chasse, Ann M Miller, Steven M Varga","doi":"10.1080/17460794.2026.2705137","DOIUrl":"10.1080/17460794.2026.2705137","url":null,"abstract":"Respiratory syncytial virus (RSV) poses a widespread global burden that typically causes mild, cold-like symptoms in infected healthy adults. However, in vulnerable populations, such as the very young or older adults, RSV infection can lead to severe and potentially fatal disease. Both viral and host factors play a dynamic role in determining disease severity. In the host, dysregulation of both the innate and adaptive immune responses can result in unrestrained viral replication and excessive inflammation. Insight has been gained into the host factors that drive more severe disease following RSV infection using animal models and clinical studies. In this review, we discuss both clinical and in vivo animal model findings to elucidate host immune responses that contribute to disease severity, highlighting pathways that may serve as beneficial therapeutic targets. PubMed, ScienceDirect and Google Scholar were accessed to search for articles up to June 2026. Eligibility criteria included in vitro, in vivo, and clinical studies evaluating the factors associated with RSV disease severity, published in peer-reviewed journals.","PeriodicalId":12505,"journal":{"name":"Future Virology","volume":"21 8","pages":"519-531"},"PeriodicalIF":1.0,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13552134/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148911523","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Building a better natural killer (NK) cell: Fc receptor engineering strategies for NK cell therapeutics. 构建更好的自然杀伤细胞：Fc受体工程策略用于NK细胞治疗。

IF 1 4区医学

Future Virology Pub Date : 2025-10-01 Epub Date: 2025-10-29 DOI: 10.1080/17460794.2025.2580187

Kyle W Kroll, Griffin Woolley, R Keith Reeves

引用次数: 0

Spillover of Rat Hepatitis E Virus into Humans: An Emerging Zoonosis? 戊型肝炎病毒在人类中的外溢：一种新出现的人畜共患病？

IF 1 4区医学

Future Virology Pub Date : 2025-08-01 Epub Date: 2025-06-26 DOI: 10.1080/17460794.2025.2522591

Kush Kumar Yadav, Menuka Bhandari, Xiang-Jin Meng, Scott P Kenney

{"title":"Spillover of Rat Hepatitis E Virus into Humans: An Emerging Zoonosis?","authors":"Kush Kumar Yadav, Menuka Bhandari, Xiang-Jin Meng, Scott P Kenney","doi":"10.1080/17460794.2025.2522591","DOIUrl":"10.1080/17460794.2025.2522591","url":null,"abstract":"Rocahepevirus ratti (rat HEV) has become a zoonotic pathogen of growing public health concern. First identified in 2010 in wild rats in Germany, Rocahepevirus ratti-C1 (HEV-C1) was genetically distinct from Paslahepevirus genotypes that cause hepatitis E in humans. Although early research indicated that HEV-C1 could not infect non-human primates, reports of human infections in Hong Kong circa 2018 raised the possibility of a new zoonoses. Currently, 23 known human instances of rat HEV infection have been reported, affecting both immunocompetent and immunocompromised individuals. A critical review of the current knowledge regarding rat HEV, including its epidemiology, zoonotic spillover, health implications, and knowledge gaps with future research directions is presented in this paper. Here we describe possible modes of transmission, human pathophysiology, and clinical signs and symptoms in infected people. The need for diagnostic tools specific for rat HEV, current detection limitations, and diagnostic challenges are also discussed. We explore potential implications for public health, stressing the value of rodent control, surveillance, and preventive measures. Knowledge gaps in the field of rat HEV research are highlighted and future lines of inquiry to reduce the potential risks to public health posed by this emerging zoonotic virus are discussed.","PeriodicalId":12505,"journal":{"name":"Future Virology","volume":"20 8","pages":"297-308"},"PeriodicalIF":1.0,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12530148/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145328699","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Live long and persist: polyomavirus immune evasion in the brain and kidney. 长寿和坚持：多瘤病毒免疫逃避在大脑和肾脏。

IF 1 4区医学

Future Virology Pub Date : 2025-07-09 DOI: 10.1080/17460794.2025.2530832

Kalynn M Alexander, Katelyn N Ayers, Aron E Lukacher

{"title":"Live long and persist: polyomavirus immune evasion in the brain and kidney.","authors":"Kalynn M Alexander, Katelyn N Ayers, Aron E Lukacher","doi":"10.1080/17460794.2025.2530832","DOIUrl":"10.1080/17460794.2025.2530832","url":null,"abstract":"Polyomaviruses (PyVs) are widespread commensals among vertebrates, including humans, where they silently persist lifelong in healthy hosts. Polyomavirus infection in immunocompromised individuals can cause life-threatening diseases. Of the 14 human polyomaviruses discovered to date, resurgent infections by the JC and BK PyVs are responsible for high morbidity and mortality in individuals with certain inherited or acquired immune perturbations. JCPyV causes several brain disorders, the most fully characterized and of highest (albeit rare) incidence being Progressive Multifocal Leukoencephalopathy (PML). BKPyV infection elicits a diffuse interstitial nephritis in up to 10% of allograft kidneys, and approximately 10% of allogeneic hematopoietic stem cell transplant recipients develop BKPyV-associated hemorrhagic cystitis. No clinically efficacious anti-PyV agents are available. Because PyVs are species-specific, determinants of pathogenesis by human PyVs are inferred from infection of cells in tissue culture. Insights into viral and immunological factors that enable PyVs to persist and cause central nervous system (CNS) and kidney disease in vivo have emerged from recent studies using mouse PyV (MuPyV), a natural murine pathogen. In this perspective, we discuss recent findings using the MuPyV-mouse model to understand early immunovirologic events of CNS and kidney infection, the development of PyV antiviral agents, and promising research directions for polyomavirology.","PeriodicalId":12505,"journal":{"name":"Future Virology","volume":" ","pages":""},"PeriodicalIF":1.0,"publicationDate":"2025-07-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12439856/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145080362","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The seropositivity of human adenovirus serotype-5 in people with obesity 肥胖人群5型人腺病毒血清阳性

4区医学

Future Virology Pub Date : 2025-03-06 DOI: 10.1080/17460794.2025.2474876

Abdullah Gümüs, Irmak Hazal Zengul, Eray Atalay, Nur Gulfem Yildiz, Murat Karameşe

引用次数: 0

The hidden impact of producer cells on virion composition and infectivity. 产生细胞对病毒粒子组成和传染性的潜在影响。

IF 1.4 4区医学

Future Virology Pub Date : 2025-01-01 Epub Date: 2025-03-12 DOI: 10.1080/17460794.2025.2475669

Gary Dunn, Matthew P Taylor

{"title":"The hidden impact of producer cells on virion composition and infectivity.","authors":"Gary Dunn, Matthew P Taylor","doi":"10.1080/17460794.2025.2475669","DOIUrl":"10.1080/17460794.2025.2475669","url":null,"abstract":"The cells infected by a virus in vivo are critical determinants of infection and disease. These same susceptible cells can also provide a wide range of options for viral propagation. The type of cell used to produce a virus, i.e. the producer cell type, can change the macromolecular composition of viruses and other factors associated with viral inoculum independent of genetic selection. Changes in the post-translational modifications of viral proteins, virion protein and lipid composition, and the types of viral structures released from different producer cells have been observed for several virus families. These producer cell-dependent changes can have wide ranging consequences on subsequent infection by altering viral tropism, antigenicity, and overall infectious capacity. The changes imparted by the producer cell impact experimental outcomes and influence viral spread and disease in vivo. In this review, we discuss the literature documenting the effects that producer cell type has on the macromolecular composition and infectious properties of virions and viral inoculum. We discuss the evidence of producer cell-dependent changes on the outcome of infection and antigenicity from diverse viral families. These observations highlight the need to better understand the impact producer cell type has on viral infections and disease.","PeriodicalId":12505,"journal":{"name":"Future Virology","volume":"20 3-4","pages":"113-123"},"PeriodicalIF":1.4,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12162045/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144301691","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Human RSVA-ON1, the only genotype present during 2019–2020 winter season in Riyadh, Saudi Arabia: a retrospective study 沙特阿拉伯利雅得 2019-2020 年冬季唯一出现的人类 RSVA-ON1 基因型：一项回顾性研究

IF 3.1 4区医学

Future Virology Pub Date : 2023-12-19 DOI: 10.2217/fvl-2023-0173

Anwar Ahmed, A. Alhetheel, Shama Parveen, F. Almajhdi, Noorah A. Alkubaisi, Muslim Mohammed Al-Saadi

引用次数: 0

Trends and perspectives in tuberculosis and HIV co-infection studies over the past three decades 过去三十年结核病和艾滋病毒双重感染研究的趋势和前景

IF 3.1 4区医学

Future Virology Pub Date : 2023-12-19 DOI: 10.2217/fvl-2023-0143

Kang Gong, Y. Lai

引用次数: 0

Rosmarinic acid inhibits Rift Valley fever virus: in vitro, computational and analytical studies 迷迭香酸抑制裂谷热病毒：体外、计算和分析研究

IF 3.1 4区医学

Future Virology Pub Date : 2023-12-19 DOI: 10.2217/fvl-2023-0119

Faten Farouk, Mohamed A Zarka, Majid Mohammed Al-Sawahli, Amr Hassan, Aly Fahmy Mohamed, Ibrahim M Ibrahim, Fafy Abd El-Rahman Mohammed, R. Shebl

{"title":"Rosmarinic acid inhibits Rift Valley fever virus: in vitro, computational and analytical studies","authors":"Faten Farouk, Mohamed A Zarka, Majid Mohammed Al-Sawahli, Amr Hassan, Aly Fahmy Mohamed, Ibrahim M Ibrahim, Fafy Abd El-Rahman Mohammed, R. Shebl","doi":"10.2217/fvl-2023-0119","DOIUrl":"https://doi.org/10.2217/fvl-2023-0119","url":null,"abstract":"Aim: The antiviral potentials of rosmarinic acid (RA) against Rift Valley fever (RVF) virus were investigated. Methods: Antiviral activity was investigated by evaluating the reduction in the viral infectivity titer. Computational and LC–MS studies were performed for investigating the mechanism of action. This is via testing the interaction between RA and its major metabolite with the key infectivity proteins and determination of RA cellular permeability. Results: A superior reduction in RVF infectivity titer (45.5%) was observed when RA was applied post-infection compared to 17.7% reduction following its application before infection in addition to time-dependent inactivation kinetics. Recorded data showed in-silico inhibitory potential of RA and its metabolite against RVFV cap-binding protein and glycoprotein C, which are integral for viral transcription. LC–MS revealed cellular inclusion of RA, supporting its intracellular viral interaction. Conclusion: These antiviral potentials might suggest a promising foundation for future anti-RVF drug development.","PeriodicalId":12505,"journal":{"name":"Future Virology","volume":" July","pages":""},"PeriodicalIF":3.1,"publicationDate":"2023-12-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138960449","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0